<document>

<filing_date>
2019-10-29
</filing_date>

<publication_date>
2020-05-07
</publication_date>

<priority_date>
2018-10-29
</priority_date>

<ipc_classes>
C07K14/725,C07K16/00,C12N5/0783,C12Q1/6881,G01N33/50
</ipc_classes>

<assignee>
BOROUGHS, ANGELA
HARVARD UNIVERSITY
MARJANOVIC, NEMO
MIT (MASSACHUSETTS INSTITUTE OF TECHNOLOGY)
OUSPENSKAIA, TAMARA
THE BROAD INSTITUTE
</assignee>

<inventors>
BOROUGHS, ANGELA
MARJANOVIC, NEMO
MAUS, MARCELA
OUSPENSKAIA, TAMARA
REGEV, AVIV
</inventors>

<docdb_family_id>
68771754
</docdb_family_id>

<title>
CAR T CELL TRANSCRIPTIONAL ATLAS
</title>

<abstract>
The invention relates to gene expression profiles and signatures of CAR T cells. The invention provides methods and compositions of CAR T cells and populations. The invention provides assays and methods of screening subjects to assess efficacy and safety of CAR T cell treatments and therapies. The invention provides assays and methods of engineering and/or administering CAR T cells to promote efficacy and safety.
</abstract>

<claims>
1. A method of identifying a candidate CAR T cell comprising:
measuring expression of a gene signature of a CAR T cell and identifying the CAR T cell as the candidate CAR T cell if the CAR T cell a gene signature selected from:
m) a E03z CAR T gene signature,
n) a costimulatory molecule gene signature,
o) a THI response gene signature,
p) a TH2 response gene signature,
q) a T cell activation gene signature,
r) any combination thereof.
2. The method of claim 1, wherein the E03z CAR T gene signature comprises one or more signature genes selected from the group consisting of:
ASB2, BIRC3, CCL3, CCL4, GGT1, CTLA4, CSF2RB, GZMB, ZP3, SDC4, XCL1, ZBED2, IFNG, CD248, FAM13A, LTB, OPN3, SOCS2, TNFRSF10A, PLXNA4, HPCAL1, and any combination thereof.
3. The method of claim 2, wherein one or more signature genes in the E03z CAR T gene signature are up-regulated, down-regulated, or both.
4. The method of claim 2, wherein the E03z CAR T gene signature comprises one or more upregulated signature genes selected from the group consisting of: ASB2, BIRC3, CCL3, CCL4, GGT1, CTLA4, CSF2RB, GZMB, ZP3, SDC4, XCL1, ZBED2, IFNG, and any combination thereof.
5. The method of claim 4, wherein the E03z CAR T gene signature comprises one or more downregulated signature genes selected from the group consisting of: CD248, FAM13A, LTB, OPN3, SOCS2, TNFRSF10A, PLXNA4, HPCAL1, and any combination thereof.
6. The method of claim 2, wherein the E03z CAR T gene signature comprises one or more downregulated signature genes selected from the group consisting of: CD248, FAM13A, LTB, OPN3, SOCS2, TNFRSF10A, PLXNA4, HPCAL1, and any combination thereof
7. The method of claim 2, wherein the E03z CAR T gene signature comprises ZP3 or GGT1.
8. The method of claim 2, wherein the E03z CAR T gene signature comprises CCL3, CCL4, GZMB, XCL1, ZBED2, IFNG, or any combination thereof.
9. The method of claim 1, wherein the costimulatory molecule gene signature comprises one or more signature genes of Table 7, Table 8, or any combination thereof.
10. The method of claim 9, wherein one or more signature genes in the costimulatory molecule gene signature are up-regulated, down-regulated, or both.
11. The method of claim 9, wherein the costimulatory molecule gene signature comprises a gene signature selected from the group consisting of:
(a) IL12RB2, JUN, EGR1, C0R07-PAM16, ARID5A, WNT5B, CDKN1A, JAKMIP1, ENPP2, JUNB, CHRNA6, Clorf 56, FAIM3, FOS, MPZL1, VNN2, MPP7, EVI2A, DMD, CRMP1, IRF8, C4orf 26, GCA, BATF3, EGR2, EGR3, SH3YL1, GIMAP2, NLN, RPS29, STMN3, LAIR1, ENOX1, ICAM1, ANKRD33B, PARP3, ITPRIPL1, ING4, ARHGAP10, ZNF672, PRDM1, RPL39, GJB2, FILIP 1L, ATHL1, FOXP1, MAPKAPK5-AS1, BBS2, ALPK2, AMICA1, CDCP1, HBEGF, SULT1B1, LIF, CDK6, Cl6orf 54, EVI2B, MINA, SLC16A3, LOC728875, CUT A, PIK3IP1, GNA15, CTTNBP2NL, HLA-DQA2, ABLIM1, RRN3P1, LINC00599, IL16, P2RY14, PRKCQ-AS1, ADCY1, GPA33, TNFSF10, FAM200B, TCEA3, TTC39C, TNFRSF8, MEGF6,ANKRD37, NTRK2, RALB, SNHG6, ANXA2R, PTBP1, MIR155HG, SOCS3, ZC4H2, SERINC5, SLC7A5, FASN, CYB5A, SDC, PLAGL2, and any combination thereof;
(b) ENPP2, ENOX1, DDIT4, JUNB, CUT A, DMD, GJB2, ARHGAP10, HLA-DQA2, GNA15, EGR1, JUN, LOC100129034, POU2F2, VOPP1, TPM4, E2F1, PLAUR, IL23R, CA2, BCL2A1, HLA-DPB1, HLA-DRB5, FILIP 1L, DNAJC6, ATHL1, UBAC1, NR5A2, NTRK2, HLA-DRB6, LZTFL1, BTN2A2, UBE2F, ENPP1, ANKRD33B, LRRC32, HLA-DRA, LHFP, HLA-DRB1, ZNF704, TXLNG, ADA, GCSAM, C4orf 26, CTH, ADRBK1, G0S2, HLA-DPA1, CD74, IL18RAP, ULBP2, F8, HLA-DOA, ARNTL2, RNF19B, IL4I1, TMEM178B, ODC1, NEK6, TBL1X, LINC00176, MED12L, DBNDD2, HBEGF, HLA-DQB2, TSHR, FSCN1, BACH2, MMD, CTTNBP2NL, RNF167, GPR132, AMICA1, ADAT2, GNPDA1, ZNF502, CXCR6, BCL2L11, PP7080, Cl0orf 54, OSM, ANK3, EPDR1, MINA, PON2, FOXP1, ELL2, P2RY14, WWTR1, ANXA3, ENPP3, DDX4, USP18, ZDHHC9, BAG1, KIF1A, TBKBP1, KIAA1671, ADCY1, TMEM189, BA, MTSS1, and any combination thereof;
(c) GJB2, NTRK2, JUNB, DGAT2, AMICA1, MSC, SH3BP5, ELL2, DNAJC6, IL12RB2, OAS3, G0S2, HLA-DQA2, DMD, HLA-DRB6, FUOM, HLA-DRA, IL4I1, ENPP2, P2RY14, C4orf 26, ADCY1, MPZL1, PDE4DIP, LAIR1, IL23R, NFE2L3, ADA, ITPR1, HLA-DRB5, TMEM165, HLA-DPA1, PDE4A, HLA-DPB1, HLA-DRB1, ZFAND5, MINA, RALB, PRKCDBP, TMEM178B, DGCR6L, ARHGEF10, ANK3, TNFRSF8, EHD4, ARID5A, IL21, SPECC1, CUT A, CTTNBP2NL, GCSAM, SH2D1A, JUN, BIRC3, EMC 8, ARHGAP10, Cl5orf 48, FBX04, KLHDC2, HAGHL, UPP1, RNF19B, RNASE6, TNIP2, BIK, SCML4, USP48, P2RY11, MATN4, NCALD, NFKBIE, CCDC88A, LOC 100132891, LHFP, MINOS 1, COL6A5, HLA-DQB2, KCNA3, SLBP, MTSS1, PAX8, FAS, DDHD2, IL21R, PIK3C2B, C9orfl6, HIVEPl, GPR132, WNT5B, NDFIP2, PLK3, NOD2, UBE2J1, PNKD, NCOA5, BATF3, VCAM1, EGR1, IRF4, EVC, RUNX2, IL31RA, ZNRF1, KDSR, IGFLR1, SEPW1, IFIH1, JMY, LOC100506668, ETV6, DENND4A, RGL4, GLUL, NOM03, CD74, ZDHHC3, NOTCH2, MAF1, CXCL10, MLLT3, HMSD, ZNF704, INSIG1, TACOl, TRIM14, TARSL2, PON2, RPL37A, SLC25A10, RGMB, TTC39C, AKIRIN1, FAM173B, CLPTM1, ANXA11, FBX032, GET4, RCN2, ALDH4A1, CD58, LYSMD2, NFKBIA, MKNK1, TMEM121, PROSER1, CIRBP, MTDH, PPP1CC, PIR, APOBR, B3GNT2, DECR1, MAP3K6, TAF4B, PCED1B, OGFOD3, Clorf 228, DNAJC5B, SLC25A22, BCL2L11, RPL21P28, TMOD1, CDKN2A, LRP8, MLLT4, ADAPl, JAK1, IFI44, MROH8, and any combination thereof;
(d) JUN, GPA33, KRT1, EGR1, CUT A, UBD, KLHL23, SCD, HLA-DOA, ALPK, CXCL10, and any combination thereof;
(e) JUN, EGR1, CIITA, GPA33, KRT1, and any combination thereof; (f) Cl7orf6l-PLSCR3, ENPP2, FILIP 1L, HLA-DQA2, UBD, CUT A, GJB2, P2RY14, IL4I1, HLA-DOA, ENOX1, HLA-DRA, NTRK2, HLA-DRB1, COL6A1, DMD, BTN2A2, HLA-DPB1, HLA-DMB, HLA-DRB5, HLA-DQB2, JUN, GCSAM, HLA-DPA1, DDIT4, HLA-DRB6, C7orf 55-LETC7L2, BCL2A, KRT7, and any combination thereof;
(g) ENPP2, FIKIP1L, HLA-DQA2, UBD, CUT A, IL4I1, ENOX1, COL6A1, BTN2A2, HLADRB5, GJB2, P2RY14, HLA-DOA, HLA-DRA, NTRK2, HLA-DPB1, HLAP-DRB1, DMD, HLA-DMB, HLA-DQB2, Cl7orf6l-PLSCR3, and any combination thereof;
(h) GJB2, UBD, NTRK, THY, HLA-DQA, HLA-DRA, G0S2, CXCL10, IER2, CUT A, DOHH, ADA, MSC, JUNB, DMD, CDK6, HLA-DRB1, HLA-DOA, SH3BP5, LGMN, ACSL1, ANXA3, HLA-DRB5, EMC 8, FILIP 1L, PDCD1, ANK3, HLA-DRB6, IFNG, MPZL1,
TMEM165, NOD2, DGAT2, AKIRIN1, ELL2, MATN4, SREBF2, INSIG1, BATF3, HLADPB1, MAF1, HLA-DPA1, ADCY1, NFKBIA, JUN, P2RY14, ANXA11, COTL1, HMHA1, IL23R, GCSAM, ZFAND5, IL21, ACADVL, IL21R, SLBP, and any combination thereof;
(i) GJB2, UBD, NTRK2, THY1, HLA-DQA, G0S2, CXCL10, DOHH, MSC, DMD, HLADOA, ANXA3, FILIP 1L, IFNG, NOD2, TMEM165, SH3BP5, HLA-DRB1, JUNB, CDK6, ACSL, HLA-DRB5, HLA-DRB6, ANK3, MPZ1, LGMN, PDCD1, and any combination thereof.
G) CXCL10, JUNB, NTRK2, MSC, VNN2 and any combination thereof;
(k) JUNB, CXCL10, ENOX1, ENPP2, DDIT4, NTRK2, GCSAM, IL5, and any combination thereof;
(l) ENPP2, GJB2, C4orf 26, MX1, NTRK2, JUNB, TNFRSF8, DGAT2, ELL2, IL4I1, ITPR1, HLA-DRB6, GCSAM, ADCY1, HLA-DQA2, HLA-DRA, ANK3, and any combination thereof;
(m) ENPP2, GJB2, C4orf 26, MX1, NTRK2, JUNB, TNFRSF8, DGAT2, ELL2, IL4I1, ITPR1, HLA-DRB6, and any combination thereof; and
(n) CUT A, CD74, HLA-DMB, HLA-DPB1, HLA-DQA2, HLA-DRB1, HLA-DRB5, HLADOA, HLA-DRA, HLA-DRB6, and any combination thereof.
12. The method of claim 11, wherein the CAR T cell is CD4+.
13. The method of claim 12, wherein the gene signature is any one of gene signatures (a)-(i).
14. The method of claim 11, wherein the CAR T cell is CD8+.
15. The method of claim 14, wherein the gene signature is any one of gene signatures (a), (b),
(c), 0), (k), (1), or (m).
16. The method of claim 11, wherein the CAR T cell is unstimulated.
17. The method of claim 16, wherein the gene signature is any one of gene signatures (a), (d),
(e), or (j).
18. The method of claim 16, wherein the CAR T cell is stimulated.
19. The method of claim 17, wherein the gene signature is any one of gene signatures (b), (c),
(f), (g), (h), (i), (k), (1), (m).
20. The method of any of claims 9-19, wherein the CAR T cell expresses a Oϋ28z costimulatory molecule.
21. The method of claim 20, wherein one or more genes in any one of gene signatures (a)-(i) is up-regulated, down-regulated, or both as compared to a CAR T cell expressing a BBz co stimulatory molecule.
22. The method of claim 21, wherein LGMN, PDCD1, GPA33, KRT1, VNN2, Cl7orfPLSCR3, and any combination thereof is up-regulated in the CART cell as compared to a CAR T expressing a BBz co-stimulatory molecule.
23. The method of claim 21, wherein IL21, IL21R, IL12RB2, IL23R, ENPP2, CUT A, CD74, HLA-DMB, HLA-DPB1, HLA-DQA2, HLA-DRB 1, HLA-DRB5, HLA-DOA, HLA-DRA, HLADRB6, and any combination thereof is down-regulated in the CART cell as compared to a CAR T expressing a BBz co-stimulatory molecule.
24. The method of any of claims 9-19, wherein the CAR T cell expresses a BBz co-stimulatory molecule.
25. The method of claim 24, wherein one or more genes in any one of gene signatures (a)-(i) is up-regulated, down-regulated, or both as compared to a CAR T cell expressing a E028z co stimulatory molecule.
26. The method of claim 25, wherein IL21, IL21R, IL12RB2, IL23R, ENPP2, CUT A, CD74, HLA-DMB, HLA-DPB1, HLA-DQA2, HLA-DRB 1, HLA-DRB5, HLA-DOA, HLA-DRA, HLADRB6, and any combination thereof is up-regulated in the CAR T cell.
27. The method of claim 26, wherein LGMN, PDCD1, GPA33, KRT1, VNN2, Cl7orfPLSCR3, and any combination thereof is down-regulated in the CART cell.
28. The method of claim 1, wherein the THI response gene signature comprises one or more signature genes selected from the group consisting of:
ERG1, TBX21, RORC, IL12RB2, GLIL1, EPPN2, DMD, IFNG, and any combination thereof.
29. The method of claim 28, wherein the CAR T cell expresses a BBz co-stimulatory molecule.
30. The method of claim 29, wherein the CAR T cell is CD4+.
31. The method of claim 1, wherein the TH2 response gene signature comprises one or more signature genes selected from the group consisting of: IL4, IL5, IL2, and any combination thereof.
32. The method of claim 31, wherein the CAR T cell expresses a E028z co-stimulatory molecule.
33. The method of claim 32, wherein the CAR T cell is CD4+.
34. The method of claim 1, wherein the T cell activation gene signature comprises one or more genes selected from Table 3, Table 4, or a combination thereof.
35. The method of claim 34, wherein the T cell activation gene signature comprises one or more genes selected from the group consisting of:
IFNG, CCL4, CCL3, IL3, XCL1, CSF2, GZMB, FABP5, XCL2, LTA, LAG3, MIR155HG, TNFRSF4, TNFRSF9, PIM3, IL13, ZBED2, PGAM1, EIF5A, IL5 and an any combination thereof.
36. The method of claim 35, wherein the stimulated CAR T cell was generated by stimulating the CAR T cell through a T cell receptor of the CAR T cell.
37. The method of claim 36, wherein IFNG, CCL4, CCL3, IL3, XCL1, CSF2, GZMB, FABP5, XCL2, LTA, LAG3, MIR155HG, TNFRSF4, TNFRSF9, PIM3, IL13, ZBED2, PGAM1, EIF5A, IL5, are upregulated as compared to a CAR T cell stimulated through a CAR of the CAR T cell.
38. The method of claim 34, wherein the T cell activation gene signature comprises one or more genes from a gene signature selected from the group consisting of:
(a) IL2RA, TUBA1B, ENOl, HSPD1, HSP90AA1, HSP90AB1, BATF3, NCL, AC133644.2, HNRNPAB, RANBP1, TPI1, NME1, TXN, CALR, SRM, RAN, CCND2, HSPE1 TNFSF10, and combinations thereof;
(b) IFNG, IL3, CCL4, XCL1, CSF2, XCL2, CCL3, LTA, GZMB, LAG3, TNFRSF9, PIM3, RGCC, NKG7, FABP5, NDFIP1, MIR155HG, SRGN, PSMA2, BCL2L1, and any combination thereof; and
(c) both (a) and (b).
39. The method of claim 38, wherein the CAR T is a stimulated CAR T cell, wherein the stimulated CAR T cell was generated by stimulating a chimeric antigen receptor of CAR T cell.
40. The method of claim 1, wherein measuring expression of a gene signature comprises bulk RNA sequencing, single cell RNA sequencing (scRNA-seq), or both.
41. The method of claim 1, further comprising isolating an identified candidate CAR T cell or a population thereof to obtain an isolated candidate CAR T cell or population thereof and optionally expanding the isolated candidate CAR T cell or population thereof to obtain an expanded candidate CAR T cell or population thereof.
43. The method of claim 42, further comprising administering the isolated candidate CAR T cell or population thereof or the expanded candidate CAR T cell or population thereof to a subject in need thereof.
44. The method of claim 43, wherein the subject in need thereof has a cancer.
45. A method of modulating a CAR T cell, comprising:
administering a modulating agent to a CAR T cell, wherein the modulating agent is capable of modifying the expression of one or more genes in the CAR T cell such that the CAR T cell comprises a gene signature selected from:
a) a CD3z CAR T gene signature,
b) a costimulatory molecule gene signature,
c) a THI response gene signature,
d) a TH2 response gene signature,
e) a T cell activation gene signature,
f) any combination thereof.
46. The method of claim 45, wherein the 003z CAR T gene signature comprises one or more signature genes selected from the group consisting of:
ASB2, BIRC3, CCL3, CCL4, GGT1, CTLA4, CSF2RB, GZMB, ZP3, SDC4, XCL1, ZBED2, IFNG, CD248, FAM13A, LTB, OPN3, SOCS2, TNFRSF10A, PLXNA4, HPCAL1, and any combination thereof.
47. The method of claim 46, wherein one or more signature genes in the E03z CAR T gene signature are up-regulated, down-regulated, or both.
48. The method of claim 46, wherein the E03z CAR T gene signature comprises one or more upregulated signature genes selected from the group consisting of: ASB2, BIRC3, CCL3, CCL4, GGT1, CTLA4, CSF2RB, GZMB, ZP3, SDC4, XCL1, ZBED2, IFNG, and any combination thereof
49. The method of claim 48, wherein the 003z CAR T gene signature comprises one or more downregulated signature genes selected from the group consisting of: CD248, FAM13A, LTB, OPN3, SOCS2, TNFRSF10A, PLXNA4, HPCAL1, and any combination thereof.
50. The method of claim 46, wherein the 003z CAR T gene signature comprises one or more downregulated signature genes selected from the group consisting of: CD248, FAM13A, LTB, OPN3, SOCS2, TNFRSF10A, PLXNA4, HPCAL1, and any combination thereof.
51. The method of claim 46, wherein the 003z CAR T gene signature comprises ZP3 or GGT1.
52. The method of claim 46, wherein the Oϋ3z CAR T gene signature comprises CCL3, CCL4, GZMB, XCL1, ZBED2, IFNG, or any combination thereof.
53. The method of claim 45, wherein the costimulatory molecule gene signature comprises one or more signature genes of Table 7, Table 8, or any combination thereof.
54. The method of claim 53, wherein one or more signature genes in the costimulatory molecule gene signature are up-regulated, down-regulated, or both.
55. The method of claim 53, wherein the costimulatory molecule gene signature comprises a gene signature selected from the group consisting of: (a) IL12RB2, JUN, EGR1, C0R07-PAM16, ARID5A, WNT5B, CDKN1A, JAKMIP1, ENPP2, JUNB, CHRNA6, Clorf 56, FAIM3, FOS, MPZL1, VNN2, MPP7, EVI2A, DMD, CRMP1, IRF8, C4orf 26, GCA, BATF3, EGR2, EGR3, SH3YL1, GIMAP2, NLN, RPS29, STMN3, LAIR1, ENOX1, ICAM1, ANKRD33B, PARP3, ITPRIPL1, ING4, ARHGAP10, ZNF672, PRDM1, RPL39, GJB2, FILIP 1L, ATHL1, FOXP1, MAPKAPK5-AS1, BBS2, ALPK2, AMICA1, CDCP1, HBEGF, SULT1B1, LIF, CDK6, Cl6orf 54, EVI2B, MINA, SLC16A3, LOC728875, CUT A, PIK3IP1, GNA15, CTTNBP2NL, HLA-DQA2, ABLIM1, RRN3P1, LINC00599, IL16, P2RY14, PRKCQ-AS1, ADCY1, GPA33, TNFSF10, FAM200B, TCEA3, TTC39C, TNFRSF8, MEGF6,ANKRD37, NTRK2, RALB, SNHG6, ANXA2R, PTBP1, MIR155HG, SOCS3, ZC4H2, SERINC5, SLC7A5, FASN, CYB5A, SDC, PLAGL2, and any combination thereof;
(b) ENPP2, ENOX1, DDIT4, JUNB, CUT A, DMD, GJB2, ARHGAP10, HLA-DQA2, GNA15, EGR1, JUN, LOC100129034, POU2F2, VOPP1, TPM4, E2F1, PLAUR, IL23R, CA2, BCL2A1, HLA-DPB1, HLA-DRB5, FILIP 1L, DNAJC6, ATHL1, UBAC1, NR5A2, NTRK2, HLA-DRB6, LZTFL1, BTN2A2, UBE2F, ENPP1, ANKRD33B, LRRC32, HLA-DRA, LHFP, HLA-DRB1, ZNF704, TXLNG, ADA, GCSAM, C4orf 26, CTH, ADRBK1, G0S2, HLA-DPA1, CD74, IL18RAP, ULBP2, F8, HLA-DOA, ARNTL2, RNF19B, IL4I1, TMEM178B, ODC1, NEK6, TBL1X, LINC00176, MED12L, DBNDD2, HBEGF, HLA-DQB2, TSHR, FSCN1, BACH2, MMD, CTTNBP2NL, RNF167, GPR132, AMICA1, ADAT2, GNPDA1, ZNF502, CXCR6, BCL2L11, PP7080, Cl0orf 54, OSM, ANK3, EPDR1, MINA, PON2, FOXP1, ELL2, P2RY14, WWTR1, ANXA3, ENPP3, DDX4, USP18, ZDHHC9, BAG1, KIF1A, TBKBP1, KIAA1671, ADCY1, TMEM189, BA, MTSS1, and any combination thereof;
(c) GJB2, NTRK2, JUNB, DGAT2, AMICA1, MSC, SH3BP5, ELL2, DNAJC6, IL12RB2, OAS3, G0S2, HLA-DQA2, DMD, HLA-DRB6, FUOM, HLA-DRA, IL4I1, ENPP2, P2RY14, C4orf 26, ADCY1, MPZL1, PDE4DIP, LAIR1, IL23R, NFE2L3, ADA, ITPR1, HLA-DRB5, TMEM165, HLA-DPA1, PDE4A, HLA-DPB1, HLA-DRB1, ZFAND5, MINA, RALB, PRKCDBP, TMEM178B, DGCR6L, ARHGEF10, ANK3, TNFRSF8, EHD4, ARID5A, IL21, SPECC1, CUT A, CTTNBP2NL, GCSAM, SH2D1A, JUN, BIRC3, EMC 8, ARHGAP10, Cl5orf 48, FBX04, KLHDC2, HAGHL, UPP1, RNF19B, RNASE6, TNIP2, BIK, SCML4, USP48, P2RY11, MATN4, NCALD, NFKBIE, CCDC88A, LOC 100132891, LHFP, MINOS 1, COL6A5, HLA-DQB2, KCNA3, SLBP, MTSS1, PAX8, FAS, DDHD2, IL21R, PIK3C2B, C9orfl6, fflVEPl, GPR132, WNT5B, NDFIP2, PLK3, NOD2, UBE2J1, PNKD, NCOA5, BATF3, VCAM1, EGR1, IRF4, EVC, RUNX2, IL31RA, ZNRF1, KDSR, IGFLR1, SEPW1, IFIH1, JMY, LOC100506668, ETV6, DENND4A, RGL4, GLUL, N0M03, CD74, ZDHHC3, NOTCH2, MAF1, CXCL10, MLLT3, HMSD, ZNF704, INSIG1, TACOl, TRIM14, TARSL2, PON2, RPL37A, SLC25A10, RGMB, TTC39C, AKIRIN1, FAM173B, CLPTM1, ANXA11, FBX032, GET4, RCN2, ALDH4A1, CD58, LYSMD2, NFKBIA, MKNK1, TMEM121, PROSER1, CIRBP, MTDH, PPP1CC, PIR, APOBR, B3GNT2, DECR1, MAP3K6, TAF4B, PCED1B, OGFOD3, Clorf 228, DNAJC5B, SLC25A22, BCL2L11, RPL21P28, TMOD1, CDKN2A, LRP8, MLLT4, ADAP1, JAK1, IFI44, MROH8, and any combination thereof;
(d) JUN, GPA33, KRT1, EGR1, CUT A, UBD, KLHL23, SCD, HLA-DOA, ALPK, CXCL10, and any combination thereof;
(e) JUN, EGR1, CIITA, GPA33, KRT1, and any combination thereof;
(f) Cl7orf6l-PLSCR3, ENPP2, FILIP 1L, HLA-DQA2, UBD, CIITA, GJB2, P2RY14, IL4I1, HLA-DOA, ENOX1, HLA-DRA, NTRK2, HLA-DRB1, COL6A1, DMD, BTN2A2, HLA-DPB1, HLA-DMB, HLA-DRB5, HLA-DQB2, JUN, GCSAM, HLA-DPA1, DDIT4, HLA-DRB6, C7orf 55-LUC7L2, BCL2A, KRT7, and any combination thereof;
(g) ENPP2, FIKIP1L, HLA-DQA2, UBD, CIITA, IL4I1, ENOX1, COL6A1, BTN2A2, HLADRB5, GJB2, P2RY14, HLA-DOA, HLA-DRA, NTRK2, HLA-DPB1, HLAP-DRB1, DMD, HLA-DMB, HLA-DQB2, Cl7orf6l-PLSCR3, and any combination thereof;
(h) GJB2, UBD, NTRK, THY, HLA-DQA, HLA-DRA, G0S2, CXCL10, IER2, CIITA, DOHH, ADA, MSC, JUNB, DMD, CDK6, HLA-DRB1, HLA-DOA, SH3BP5, LGMN, ACSL1, ANXA3, HLA-DRB5, EMC 8, FILIP 1L, PDCD1, ANK3, HLA-DRB6, IFNG, MPZL1,
TMEM165, NOD2, DGAT2, AKIRIN1, ELL2, MATN4, SREBF2, INSIG1, BATF3, HLADPB1, MAF1, HLA-DPA1, ADCY1, NFKBIA, JUN, P2RY14, ANXA11, COTL1, HMHA1, IL23R, GCSAM, ZFAND5, IL21, ACADVL, IL21R, SLBP, and any combination thereof;
(i) GJB2, UBD, NTRK2, THY1, HLA-DQA, G0S2, CXCL10, DOHH, MSC, DMD, HLADOA, ANXA3, FILIP 1L, IFNG, NOD2, TMEM165, SH3BP5, HLA-DRB1, JUNB, CDK6, ACSL, HLA-DRB5, HLA-DRB6, ANK3, MPZ1, LGMN, PDCD1, and any combination thereof.
G) CXCL10, JUNB, NTRK2, MSC, VNN2 and any combination thereof; (k) JUNB, CXCL10, ENOX1, ENPP2, DDIT4, NTRK2, GCSAM, IL5, and any combination thereof;
(l) ENPP2, GJB2, C4orf 26, MX1, NTRK2, JUNB, TNFRSF8, DGAT2, ELL2, IL4I1, ITPR1, HLA-DRB6, GCSAM, ADCY1, HLA-DQA2, HLA-DRA, ANK3, and any combination thereof;
(m) ENPP2, GJB2, C4orf 26, MX1, NTRK2, JUNB, TNFRSF8, DGAT2, ELL2, IL4I1, ITPR1, HLA-DRB6, and any combination thereof; and
(n) CUT A, CD74, HLA-DMB, HLA-DPB1, HLA-DQA2, HLA-DRB1, HLA-DRB5, HLA-DOA, HLA-DRA, HLA-DRB6, and any combination thereof.
56. The method of claim 55, wherein the gene signature is any one of gene signatures (a)-(i).
57. The method of claim 55, wherein the gene signature is any one of gene signatures (a), (b), (c), (j), (k), (1), or (m).
58. The method of claim 55, wherein the gene signature is any one of gene signatures (a), (d),
(e), or (j).
59. The method of claim 55, wherein the gene signature is any one of gene signatures (b), (c),
(f), (g), (h), (i), (k), (1), or (m).
60. The method of claim 55, wherein one or more genes in any one of gene signatures (a)-(i) is overexperssed, underexpressed, or both as compared to an unmodified CAR T cell.
61. The method of claim 60, wherein LGMN, PDCD1, GPA33, KRT1, VNN2, Cl7orfPLSCR3, and any combination thereof is overexpressed in the CART cell.
62. The method of claim 60, wherein IL21, IL21R, IL12RB2, IL23R, ENPP2, CUT A, CD74, HLA-DMB, HLA-DPB1, HLA-DQA2, HLA-DRB 1, HLA-DRB5, HLA-DOA, HLA-DRA, HLADRB6, and any combination thereof is underexpressed in the CART cell.
63. The method of claim 60, wherein IL21, IL21R, IL12RB2, IL23R, ENPP2, CUT A, CD74, HLA-DMB, HLA-DPB1, HLA-DQA2, HLA-DRB 1, HLA-DRB5, HLA-DOA, HLA-DRA, HLADRB6, and any combination thereof is overexpressed in the CAR T cell.
64. The method of claim 60, wherein LGMN, PDCD1, GPA33, KRT1, VNN2, Cl7orfPLSCR3, and any combination thereof is underexpressed in the CART cell.
65. The method of claim 45, wherein the THI response gene signature comprises one or more signature genes selected from the group consisting of:
ERG1, TBX21, RORC, IL12RB2, GLIL1, EPPN2, DMD, IFNG, and any combination thereof.
66. The method of claim 45, wherein the TH2 response gene signature comprises one or more signature genes selected from the group consisting of: IL4, IL5, IL2, and any combination thereof.
67. The method of claim 45, wherein the T cell activation gene signature comprises one or more genes selected from Table 3, Table 4, or a combination thereof.
68. The method of claim 67, wherein the T cell activation gene signature comprises one or more genes selected from the group consisting of:
IFNG, CCL4, CCL3, IL3, XCL1, CSF2, GZMB, FABP5, XCL2, LTA, LAG3, MIR155HG, TNFRSF4, TNFRSF9, PIM3, IL13, ZBED2, PGAM1, EIF5A, IL5 and an any combination thereof.
69. The method of claim 68, wherein IFNG, CCL4, CCL3, IL3, XCL1, CSF2, GZMB, FABP5, XCL2, LTA, LAG3, MIR155HG, TNFRSF4, TNFRSF9, PIM3, IL13, ZBED2, PGAM1, EIF5A, IL5, are overexpressed or underexpressed in the CAR T cell.
70. The method of claim 67, wherein the T cell activation gene signature comprises one or more genes from a gene signature selected from the group consisting of: (a) IL2RA, TUBA1B, ENOl, HSPD1, HSP90AA1, HSP90AB1, BATF3, NCL, AC133644.2, HNRNPAB, RANBP 1 , TPI1, NME1, TXN, CALR, SRM, RAN, CCND2, HSPE1 TNFSF10, and combinations thereof;
(b) IFNG, IL3, CCL4, XCL1, CSF2, XCL2, CCL3, LTA, GZMB, LAG3, TNFRSF9, PIM3, RGCC, NKG7, FABP5, NDFIP1, MIR155HG, SRGN, PSMA2, BCL2L1, and any combination thereof; and
(c) both (a) and (b).
71. The method of claim 45, wherein the modifying agent is a therapeutic antibody, antibody fragment, antibody-like protein scaffold, aptamer, polypeptide, protein, genetic modifying agent, small molecule, small molecule degrader, or combination thereof.
72. The method of claim 71, wherein the genetic modifying agent is a CRISPR-Cas system, a TALEN, a Zn-fmger nuclease, or a meganuclease.
73. An isolated or engineered CAR T cell obtained according the method of any of claims 45- 72.
74. A method of treating a disease in a subject in need thereof comprising:
administering an identified candidate cell obtained by the method as in any one of claims
1-44 or an isolated or engineered CAR T cell as in claim 73, or a cell population thereof to the subject.
75. The method of claim 74, where the disease is a cancer.
76. The method of claim 74, further comprising administering an additional agent, therapy, antineoplastic or antitumor agent or radiation and/or surgical therapy or an antigen or a neoantigen.
77. The method of claim 76, wherein the additional agent, therapy, antineoplastic or antitumor agent or radiation and/or surgical therapy or an antigen or neoantigen is administered sequentially or concurrently.
78. The method of claim 77, wherein the sequential administration comprises a time period of a day, two days, three days, four days, five days, six days, a week, two weeks, thee weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks, or more.
79. A method of screening for one or more agents capable of modifying a gene expression signature of a CAR T cell as in any one of claims 45-72, comprising:
contacting an unmodified CAR T cell population with a test modulating agent or a library of modulating agents;
identifying candidate CAR T cells present in the CART T cell population by the method of any one of claims 1-44; and
selecting modulating agents that result in increasing the number of candidate CAR T cells present in the CAR T cell population.
80. The method of any one of claims 1-79, wherein the CAR T cell or population thereof is obtained from or derived from a subject to be treated.
</claims>
</document>
